Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Pfizer axes ex-Metsera obesity asset and GIPR prospect in quarterly clearout

Pfizer axes ex-Metsera obesity asset and GIPR prospect in quarterly clearout

  • August 4, 2026

Pfizer has axed two clinical-stage obesity programs, dropping a GLP-1 receptor agonist from the Metsera buyout and a GIPR antagonist as part of its quarterly pipeline cleanout.

Leave A Comment

Fields (*) Mark are Required